CARDIALEN
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition. It was founded in 2008 and headquartered in Minneapolis, Minnesota.
CARDIALEN
Industry:
Biotechnology Life Science Medical Device
Founded:
2008-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.cardialen.com
Total Employee:
11+
Status:
Active
Contact:
314-615-6941
Email Addresses:
[email protected]
Total Funding:
34.79 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail Google Google Cloud
Similar Organizations
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Convertible Note - CardiaLen
National Institutes of Health
National Institutes of Health investment in Grant - CardiaLen
Qiming Venture Partners
Qiming Venture Partners investment in Series B - CardiaLen
Cultivation Capital
Cultivation Capital investment in Series B - CardiaLen
RiverVest
RiverVest investment in Series B - CardiaLen
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - CardiaLen
Cultivation Capital
Cultivation Capital investment in Venture Round - CardiaLen
BELLE Capital
BELLE Capital investment in Series B - CardiaLen
Twin Cities Angels
Twin Cities Angels investment in Series B - CardiaLen
The Lambda Funds
The Lambda Funds investment in Series B - CardiaLen
Official Site Inspections
http://www.cardialen.com
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "CardiaLen"
CardiaLen - Crunchbase Company Profile & Funding
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters …See details»
About Cardialen — MaxWell Biomedical
Maxwell Biomedical completes acquision of Cardialen assets. Cardialen, a Minneapolis, MN based company, developed MultiPulse™ Therapy (MPT™), a low-energy defibrillation and …See details»
Cardialen Company Profile 2024: Valuation, Investors ... - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for Cardialen. Use the PitchBook Platform to explore the full profile.See details»
Cardialen Acquision — MaxWell Biomedical
SAN DIEGO, Calif., December 8 2022 Maxwell Biomedical announced today that it has completed the acquisition of Cardialen’s assets. Cardialen, a Minneapolis, MN based company developed …See details»
Cardialen - Products, Competitors, Financials, Employees, …
Headquarters Location. 6160 Summit Drive North, Suite 450 . Minneapolis, Minnesota, 55430, United States. 612-208-1260See details»
Cardialen Company Profile - Office Locations, Competitors ... - Craft
See insights on Cardialen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
CardiaLen - Contacts, Employees, Board Members, Advisors
Edit Board Member and Advisor Profiles Section. Number of Board Member and Advisor Profiles 2. CardiaLen has 2 board members and advisors, including William Schmidt.See details»
CardiaLen - Crunchbase
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.See details»
Cardialen | Minneapolis, MN, USA Startup - gust.com
Cardialen is an early-stage medical device company developing a revolutionary therapy to treat Atrial Fibrillation (AF). AF is the most common cardiac arrhythmia encountered in clinical …See details»
Cardialen, Inc Overview | SignalHire Company Profile
Cardialen, Inc is a private company that has been in the industry for 15 years. The company currently specializes in the Medical Devices, Health Care Equipment areas. The position of the …See details»
CardiaLen | St. Louis BioTech Startup Exit | EQ
Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillation therapy using low-electrical energy designed to more gently restore normal heart rhythm and potentially …See details»
Maxwell Biomedical Completes Acquisition of Cardialen’s Assets
Dec 14, 2022 Acquisition expands the Maxwell Biomedical product and intellectual property portfolio. SAN DIEGO, Dec. 14, 2022 /PRNewswire/ — Maxwell Biomedical announced today …See details»
CardiaLen's Leadership Team - Team at CardiaLen - The Org
CardiaLen's Leadership Team. CardiaLen's Leadership Team includes Kristen Swanson and 6 others.See details»
Cardialen in the News — MaxWell Biomedical
Minneapolis, Nov. 17, 2021 – Cardialen, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin a clinical trial of …See details»
Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy ...
Jan 19, 2021 MINNEAPOLIS--(BUSINESS WIRE)--Cardialen, Inc., has been awarded a $2.8 million National Institutes of Health (NIH) Phase II SBIR grant to further the clinical study of …See details»
Low-Shock Defibrillator Maker Cardialen Inc. Raises $17M
Oct 11, 2018 Home; Health Care + Med Tech | Low-Shock Defibrillator Maker Cardialen Inc. Raises $17M ; Cardialen president and CEO Jeff Peters Cardialen Inc. Cardialen Inc.See details»
Cardialen raises $17M for a gentler, low-energy defibrillator
Oct 10, 2018 Cardialen raised $17 million to fund its work on a low-energy defibrillator that aims to more gently restore a normal heart rhythm, with the goal of developing an implantable …See details»
Cardialen gets FDA approval for study of MultiPulse Therapy
Nov 18, 2021 Cardialen has obtained approval from the the US Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to commence clinical trial of its MultiPulse …See details»
Cardialen gets FDA approval for study of its Multipulse Therapy …
Nov 17, 2021 Cardialen has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) to begin a clinical trial of its Multipulse Therapy …See details»
Cardialen gets FDA IDE nod for low-energy AFib treatment
Nov 17, 2021 Cardialen announced today that it received FDA investigational device exemption (IDE) approval for its MultiPulse therapy platform.. Minneapolis-based Cardialen designed its …See details»